255
Participants
Start Date
November 9, 2015
Primary Completion Date
March 27, 2019
Study Completion Date
March 15, 2021
cabazitaxel XRP6258
Pharmaceutical form: solution Route of administration: intravenous
enzalutamide
Pharmaceutical form: capsule Route of administration: oral
abiraterone acetate
Pharmaceutical form: tablet Route of administration: oral
prednisone
Pharmaceutical form: tablet Route of administration: oral
Investigational Site Number 352001, Reykjavik
Investigational Site Number 056003, Brussels
Investigational Site Number 056007, Brussels
Investigational Site Number 040003, Vienna
Investigational Site Number 040004, Vienna
Investigational Site Number 578001, Grålum
Investigational Site Number 056005, Leuven
Investigational Site Number 040002, Linz
Investigational Site Number 578002, Trondheim
Investigational Site Number 056013, Bruges
Investigational Site Number 056001, Ghent
Investigational Site Number 300001, Athens
Investigational Site Number 250004, Marseille
Investigational Site Number 203003, Prague
Investigational Site Number 276008, Berlin
Investigational Site Number 300005, Marousi, Athens
Investigational Site Number 276010, Rostock
Investigational Site Number 250014, Plérin
Investigational Site Number 276025, Lübeck
Investigational Site Number 380004, Brescia
Investigational Site Number 724004, Madrid
Investigational Site Number 724002, Madrid
Investigational Site Number 203002, Pilsen
Investigational Site Number 250011, Montpellier
Investigational Site Number 250008, Tours
Investigational Site Number 276007, Göttingen
Investigational Site Number 276004, Magdeburg
Investigational Site Number 724003, Seville
Investigational Site Number 276023, Essen
Investigational Site Number 276022, Duisburg
Investigational Site Number 276006, Münster
Investigational Site Number 300004, Thessaloniki
Investigational Site Number 276002, Frankfurt am Main
Investigational Site Number 250010, Clermont-Ferrand
Investigational Site Number 276028, Aschaffenburg
Investigational Site Number 203005, Brno
Investigational Site Number 250009, Strasbourg
Investigational Site Number 276018, Mannheim
Investigational Site Number 250006, Lyon
Investigational Site Number 276011, Tübingen
Investigational Site Number 276003, Nürtingen
Investigational Site Number 250013, Paris
Investigational Site Number 250007, Paris
Investigational Site Number 250002, Paris
Investigational Site Number 203001, Olomouc
Investigational Site Number 250005, Suresnes
Investigational Site Number 250018, Saint-Mandé
Investigational Site Number 250001, Villejuif
Investigational Site Number 056006, Charleroi
Investigational Site Number 250016, Reims
Investigational Site Number 372001, Dublin
Investigational Site Number 372003, Dublin
Investigational Site Number 380005, Candiolo
Investigational Site Number 380009, Meldola
Investigational Site Number 380006, Napoli
Investigational Site Number 380002, Pisa
Investigational Site Number 380008, Verona
Investigational Site Number 276026, Jena
Investigational Site Number 380001, Roma
Investigational Site Number 528002, Breda
Investigational Site Number 528003, Nijmegen
Investigational Site Number 528005, Rotterdam
Investigational Site Number 528004, Sittard-Geleen
Investigational Site Number 724001, Barcelona
Investigational Site Number 826001, Sutton
Lead Sponsor
Sanofi
INDUSTRY